Congressional Problem Solvers Caucus Endorses RESULTS Act
A bipartisan congressional caucus recently announced its endorsement of the Reforming and Enhancing Sustainable Updates to Laboratory Testing...
1 min read
On May 29, Medicare announced it would expand coverage for genomic sequence analysis panels in the treatment of hematolymphoid diseases.
The local coverage determination (LCD) “provides limited coverage for genomic sequence analysis panels under specific clinical circumstances.” Specifically, these multi-gene panel tests would be used for diagnosis, risk stratification, and treatment planning for patients with hematolymphoid diseases, including newly diagnosed or relapsed/refractory acute myelogenous leukemia, myelodysplastic syndromes with nondiagnostic assessments, and myeloproliferative neoplasms requiring risk stratification or disease monitoring.
The College of American Pathologists applauded the proposed updates in a 2024 letter, expressing support for the decision to broaden coverage. According to CAP, the policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
The revision is effective for services performed on or after July 13, 2025.
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/june-10-2025#story5
Senate HELP Committee Votes to Advance Price Transparency Legislation
On July 22, the Senate Health, Education, Labor, and Pensions (HELP) Committee voted to advance the Patients Deserve Price Tags Act (S.2355) by a...
The Rise of CLIA-Related Rejections: What Labs Should Review
Since CMS transitioned CLIA certification to a paperless system in March, TELCOR has noticed an increase in CLIA-related rejections and denials from...